Drugs / MVA HIV-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01571466 | Sep 2011 → May 2013 | HIV infectious disease | Hospital Clinic of Barcelona | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA HIV-B | “Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)” NCT01571466 ↗ |
| Known as | MVA-B | “A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.” PMID 26544853 ↗ Nov 2015 |
| Modality | Vaccine | “modified vaccinia Ankara-based HIV-1 vaccine (MVA-B)” PMID 25724985 ↗ Feb 2015 |
| Route | Intramuscular | “3 intramuscular injections of MVA-B vaccine” PMID 26544853 ↗ Nov 2015 |